Asst Prof Raymond Ng Chee Hui

Assistant Professor Ng graduated from Otago Medical School in New Zealand in 1994 and subse-quently attained his specialist oncology fellowship from the Royal Australasian College of Physi-cians in 2004. Following this he spent a year as a Clinical Research Fellow at Royal Melbourne Hospital in Australia and subsequently an additional two years as a Clinical Fellow at Princess Margaret Hospital in Toronto, Canada. His work in Canada focused primarily on clinical care as well as a special interest on health outcomes research in breast and lung cancer.

He returned to Singapore in 2007 as an Associate Consultant at the National Cancer Centre Singapore and is now currently a Senior Consultant within the breast oncology team. In this intervening period he also completed a Master in Public Health from NUS in 2010.

He is passionate about medical education and spends part of his time every week lecturing and men-toring medical students at the University. In addition to his clinical and educational duties, he also provides consultation work with the Agency for Care Effectiveness at the Ministry of Health.

• MPH, National University of Singapore
• FRACP (Medical Oncology) Royal Australasian College of Physicians 
• Dip Obs - University of Otago, New Zealand 
• MB, ChB - University of Otago, New Zealand
  

• Chairman 2025, Joint Committee on Specialist Training Examination Committee 
• Consultant 2023-current, Agency for Care Effectiveness, Ministry of Health Singapore 
• Deputy Chair 2022-current, Drug Advisory Committee (Oncology Drug Subcommittee), Ministry of Health Singapore 
• Member 2024-current, Pharmacy Residents Selection Committee 
• Member, Singapore Society of Oncology 
• Member, Royal Australasian College of Physicians

• Gold Award 2025, Singapore Health Quality Service Awards 
• Senior Educator Award 2021, Medicine ACP Education Awards 
• Silver Award 2016, Singapore Health Quality Service Awards 
• Gold Award 2010, Singapore Health Quality Service Awards

• Wong WHM, Ng R, Aziz MIA, Ong BS, Ng K. Cost-effectiveness analysis of trastuzumab emtansine for second-line treatment of HER2+ advanced breast cancer in Singapore. Expert Rev Pharmacoecon Outcomes Res. 2025 Jan 22;1-9. 
• Tan SH, Goh LGH, Ong BSK, Ng DSG, Lin L, Ng RCH, Thong BY, Ng K. Impact of Value-Driven Healthcare Strategies for Biosimilar Adoption: The Singapore Story. Pharmacoecon Open. 2024 Sep;8(5):679-688. 
• Khor CC, Winter S, Sutiman N, Mürdter TE, Chen S, Lim JSL, Li Z, Li J, Sim KS, Ganchev B, Eccles D, Eccles B, Tapper W, Zgheib NK, Tfayli A, Ng RCH, Yap YS, Lim E, Wong M, Wong NS, Ang PCS, Dent R, Tremmel R, Klein K, Schaeffeler E, Zhou Y, Lauschke VM, Eichelbaum M, Schwab M, Brauch HB, Chowbay B, Schroth W. Cross-Ancestry Genome-Wide Association Study Defines the Extended CYP2D6 Locus as the Principal Genetic De-terminant of Endoxifen Plasma Concentrations. Clin Pharmacol Ther. 2023 Mar;113(3):712-723. 
• Lim GH, Alcantara VS, Ng RP, Ng R, Allen JC, Htein MMW, Lim SH, Yan Z, Tan QT. Patterns of breast cancer second recurrences in patients after mastectomy. Breast Cancer Res Treat. 2022 Dec;196(3):583-589. 
• Qi TH, Hian OH, Kumaran AM, Tan TJ, Cong TRY, Su-Xin GL, Lim EH, Ng R, Yeo MCR, Tching FLLW, Zewen Z, Hui CYS, Xin WR, Ooi SKG, Leong LCH, Tan SM, Preetha M, Sim Y, Tan VKM, Yeong J, Yong WF, Cai Y, Nei WL. Multi-center evaluation of artificial intel-ligent imaging and clinical models for predicting neoadjuvant chemotherapy response in breast cancer. Breast Cancer Res Treat. 2022 May;193(1):121-138. 
• Kong SL, Liu X, Tan SJ, Tai JA, Phua LY, Poh HM, Yeo T, Chua YW, Haw YX, Ling WH, Ng RCH, Tan TJ, Loh KWJ, Tan DS, Ng QS, Ang MK, Toh CK, Lee YF, Lim CT, Lim TKH, Hillmer AM, Yap YS, Lim WT. Complementary Sequential Circulating Tumor Cell (CTC) and Cell-Free Tumor DNA (ctDNA) Profiling Reveals Metastatic Heterogeneity and Ge-nomic Changes in Lung Cancer and Breast Cancer. Front Oncol. 2021;11:698551. 
• Kleftogiannis D, Ho D, Liew JX, Poon PSY, Gan A, Ng RC, Tan BK, Tay KH, Lim SH, Tan GS, Shih CC, Lim TK, Lee AS, Tan IB, Yap YS, Ng SB. Detection of genomic alterations in breast cancer with circulating tumour DNA sequencing. Sci Rep. 2020 Oct 8;10(1):16774. 
• Yap NY, Tan NYT, Tan CJ, Loh KW, Ng RCH, Ho HK, Chan A. Associations of plasma brain-derived neurotrophic factor (BDNF) and Val66Met polymorphism (rs6265) with long-term cancer-related cognitive impairment in survivors of breast cancer. Breast Cancer Res Treat. 2020 Oct;183(3):683-696. 
• Yap YS, Leong MC, Chua YW, Loh KWJ, Lee GE, Lim EH, Dent R, Ng RCH, Lim JH, Singh G, Tan A, Guan G, Wu A, Lee YF, Bhagat AAS, Lim DW. Detection and prognostic relevance of circulating tumour cells (CTCs) in Asian breast cancers using a label-free mi-crofluidic platform. PLoS One. 2019;14(9):e0221305. 
• Tan CJ, Lim SWT, Toh YL, Ng T, Yeo A, Shwe M, Foo KM, Chu P, Jain A, Koo SL, Dent RA, Ng RCH, Yap YS, Lim EH, Loh KW, Chay WY, Lee GE, Tan TJY, Beh SY, Wong M, Chan JJ, Khor CC, Ho HK, Chan A. Replication and Meta-analysis of the Association be-tween BDNF Val66Met Polymorphism and Cognitive Impairment in Patients Receiving Chemotherapy. Mol Neurobiol. 2019 Jul;56(7):4741-4750. 
• Chae JW, Ng R, Chan A. Chemotherapy drug concentrations in hair follicles: a potential bi-omarker to monitor the effectiveness of scalp cooling for chemotherapy-induced alopecia. Support Care Cancer. 2018 Nov;26(11):3669-3670. 
• Ng T, Phey XY, Yeo HL, Shwe M, Gan YX, Ng R, Ho HK, Chan A. Impact of Adjuvant An-thracycline-Based and Taxane-Based Chemotherapy on Plasma VEGF Levels and Cognitive Function in Breast Cancer Patients: A Longitudinal Study. Clin Breast Cancer. 2018 Oct;18(5):e927-e937. 
• Lee CF, Ng R, Luo N, Cheung YB. Development of Conversion Functions Mapping the FACT-B Total Score to the EQ-5D-5L Utility Value by Three Linking Methods and Compar-ison with the Ordinary Least Square Method. Appl Health Econ Health Policy. 2018 Oct;16(5):685-695. 
• Yap YS, Singh AP, Lim JHC, Ahn JH, Jung KH, Kim J, Dent RA, Ng RCH, Kim SB, Chiang DY. Elucidating therapeutic molecular targets in premenopausal Asian women with recurrent breast cancers. NPJ Breast Cancer. 2018;4:19. 
• Ng T, Dorajoo SR, Cheung YT, Lam YC, Yeo HL, Shwe M, Gan YX, Foo KM, Loh WK, Koo SL, Jain A, Lee GE, Dent R, Yap YS, Ng R, Chan A. Distinct and heterogeneous trajec-tories of self-perceived cognitive impairment among Asian breast cancer survi-vors. Psychooncology. 2018 Apr;27(4):1185-1192. 
• Publication link: https://www.ncbi.nlm.nih.gov/myncbi/1L7uj0E0U5n5i/bibliography/public/